Theracryf (LON:TCF – Get Free Report) posted its quarterly earnings results on Monday. The company reported GBX (0.16) EPS for the quarter, Digital Look Earnings reports. Theracryf had a negative net margin of 792.17% and a negative return on equity of 93.92%.
Theracryf Trading Up 5.1%
TCF opened at GBX 0.18 on Wednesday. The stock has a fifty day moving average price of GBX 0.19 and a 200 day moving average price of GBX 0.21. Theracryf has a 1 year low of GBX 0.16 and a 1 year high of GBX 0.27. The stock has a market cap of £3.95 million, a price-to-earnings ratio of -1.42 and a beta of 1.37.
About Theracryf
The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy.
Featured Stories
- Five stocks we like better than Theracryf
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
Receive News & Ratings for Theracryf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theracryf and related companies with MarketBeat.com's FREE daily email newsletter.
